Long-term Tamoxifen use, as widely promoted by oncologists for women following breast cancer, turns out to increase the risk of highly aggressive hormone receptor-negative breast cancer by 440%. This means that while Tamoxifen reduces the risk for less invasive estrogen positive cancer by 60%, it is at the same time putting many women in extreme peril.
Read More: breast cancer,
LeptiCardio Pack™,
Leptin Control Pack®,
Leptinal®,
LeptiSlim®,
Tamoxifen